A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Brief description of study
If you have been diagnosed with mantle cell lymphoma that has relapsed or refractory (lymphoma that has either come back or progressed on treatment), you may qualify for this Phase I/II study. The main goal of this study is to see whether the addition of ixazomib to ibrutinib chemotherapy is effective in treating people who have relapsed or refractory mantle cell lymphoma and to examine the side effects associated with ixazomib in combination with ibrutinib.
Clinical Study Identifier: s17-00793
ClinicalTrials.gov Identifier: NCT03323151
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
